NCT05611957View on ClinicalTrials.gov

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions
HealthyRenal Insufficiency
Interventions
DRUG

LY3437943

Administered SC.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

55114

Nucleus Networks, Saint Paul

92780

Orange County Research Center, Tustin

33014-3616

Clinical Pharmacology of Miami, Miami

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY